author-photo

Derek Mendy

Celgene

24

Papers

1033

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Discovery of CRBNE3 Ligase Modulator CC-92480 forthe Treatment of Relapsed and Refractory Multiple Myeloma

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (0)
CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

2019 Blood
Show All
- Source
- Cite
- Save
Citations (8)
CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Author response: UBE2G1 governs the destruction of cereblon neomorphic substrates

2018 eLife
Show All
- Source
- Cite
- Save
Citations (0)
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.

2016 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (28)
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.

2014 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (80)
Absence of mutations in cereblon ( CRBN ) and DNA damage-binding protein 1 ( DDB1 ) genes and significance for IMiD therapy

2014 Leukemia
Show All
- Source
- Cite
- Save
Citations (37)
The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

2013 Blood
Show All
- Source
- Cite
- Save
Citations (1)
mediated cell cycle arrest, and activation of autophagy

2013
Show All
- Source
- Cite
- Save
Citations (0)
Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias

2012 Blood
Show All
- Source
- Cite
- Save
Citations (2)